Diabetologia
-
Publication Venue For
- Erratum to: Innovative technology shows impact of glycaemic control on peripheral retinal vessels in adolescents with type 1 diabetes (Diabetologia, 10.1007/s00125-017-4375-3). 60:2541. 2017
- Gestational retinal microvasculature and the risk of 5 year postpartum abnormal glucose metabolism.. 60:2368-2376. 2017
- Retinal vascular geometry and 6 year incidence and progression of diabetic retinopathy.. 60:1770-1781. 2017
- Retinal microvascular calibre and risk of diabetes mellitus: a systematic review and participant-level meta-analysis.. 58:2476-2485. 2015
- PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy.. 58:1309-1318. 2015
- Can delaying the onset of type 2 diabetes be cost-effective?. 57:S120-S121. 2014
- Eighteen year weight trajectories and metabolic markers of diabetes in modernising China.. 57:1820-1829. 2014
- Sex-specific differences in prevention of type 2 diabetes mellitus: a systematic review and meta-analysis. 57:S120-S120. 2014
- Multilevel examination of diabetes in modernising China: what elements of urbanisation are most associated with diabetes?. 55:3182-3192. 2012
- State of diabetes-related trials in the clinicaltrials.gov dataset. 55:S90-S91. 2012
- Multiple genetic variants explain measurable variance in type 2 diabetes-related traits in Pakistanis.. 55:2193-2204. 2012
- Long-term ezetimibe/simvastatin (E/S) plus extended release niacin (N) treatment in hyperlipidaemic patients with diabetes and metabolic syndrome. 52:S483-S483. 2009
- Microarray analysis of multiple candidate genes and associated plasma proteins for nephropathy secondary to type 2 diabetes among Chinese individuals.. 52:1343-1351. 2009
- Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score--the CoLaus Study.. 52:600-608. 2009
- Effect of ezctimibe/sinivastatin (E/S) versus atorvastatin (A) on lipoprotein subclasses in type 2 diabetes (T2DM) patients with hypercholesterolaemia (HC). 51:S339-S339. 2008
- The relationship of retinal vascular calibre to diabetes and retinopathy: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study.. 50:2263-2271. 2007
- Carnitine revisited: potential use as adjunctive treatment in diabetes.. 50:824-832. 2007
- Is omega-3 key to unlocking inflammation in obesity?. 49:1999-2001. 2006
- Association study of genetic polymorphisms of SLC2A10 gene and type 2 diabetes in the Taiwanese population.. 49:1214-1221. 2006
- Protein kinase-zeta interacts with munc18c: role in GLUT4 trafficking.. 48:1627-1636. 2005
- Generation of hydrogen peroxide and failure of antioxidative responses in pancreatic islets of male C57BL/6 mice are associated with diabetes induced by multiple low doses of streptozotocin.. 47:676-685. 2004
- The W64R variant of the beta3-adrenergic receptor is not associated with type II diabetes or obesity in a large Finnish sample.. 42:238-244. 1999
- Identification of genetic markers to 20 NIDDM candidate genes by radiation hybrid analysis.. 41:366-367. 1998
- Anti-GAD antibodies in Chinese patients with youth and adult-onset IDDM and NIDDM.. 40:1425-1430. 1997
- Engineered cell lines for insulin replacement in diabetes: current status and future prospects.. 40 Suppl 2:S42-S47. 1997
- UDP-N-acetylglucosamine transferase and glutamine: fructose 6-phosphate amidotransferase activities in insulin-sensitive tissues.. 40:76-81. 1997
- Demonstration of a relatively hepatoselective effect of covalent insulin dimers on glucose metabolism in dogs.. 38:1007-1013. 1995
- Transgenic mice overproducing islet amyloid polypeptide have increased insulin storage and secretion in vitro.. 37:725-728. 1994
- Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway.. 36:570-573. 1993
- Type 2 (non-insulin-dependent) diabetes mellitus, migration and westernisation: the Tokelau Island Migrant Study.. 32:585-590. 1989
- An examination of the role of insulin dimerisation and negative cooperativity using the biological properties of the despentapeptide and deshexapeptide insulins.. 30:733-738. 1987
- Number and affinity of insulin receptors in intact human subjects.. 27:207-211. 1984
- Covalently-linked insulin dimers: their metabolism and biological effects in vivo as partial competitive antagonists of insulin clearance.. 27:27-31. 1984
- Mechanism of action of insulin and insulin analogues. A comparison of the hepatic and peripheral effects on glucose turnover of insulin, proinsulin and three insulin analogues modified at positions A1 and B29.. 20:94-101. 1981
- Therapy of malignant hamster insulinomas with monoamine precursors.. 20:148-154. 1981
- Radioimmunoassay of chemically modified insulins.. 18:59-63. 1980
- Monoamine oxidase and catechol-O-methyltransferase activity in hamster and rat insulinomas.. 17:249-256. 1979
- The influence of genetic background on the susceptibility of mice to diabetes induced by alloxan and on recovery from alloxan diabetes.. 17:187-191. 1979
- In vitro bioactivity of insulin analogues: lipogenic and anti-lipolytic potency and their interaction with the effect of native insulin.. 15:403-410. 1978
- B1-3,5-diiodotyrosine insulin: a valid tracer for insulin.. 13:257-261. 1977
- Biological properties of chemically modified insulins. I. Biological activity of proinsulin and insulin modified at A1-glycine and B29-lysine.. 12:601-608. 1976
- Cardiovascular safety and efficacy of exenatide once-weekly in patients with moderate renal dysfunction in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) 2018
- Changes in serum calcitonin concentrations and incidence of adjudicated medullary thyroid carcinoma in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) 2018
- Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL 2018
- Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial 2018
- Potential impact of differential drop-in of open-label diabetes medications in EXSCEL 2018
- Anti-apolipoprotein A-I antibodies in patients with type 2 diabetes: epitope mapping 2017
- Resource use and UK-perspective costs in patients with type 2 diabetes during the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) 2017
- Risk of pancreatic diseases by second-line anti diabetes drug class: real world based evidence 2017
- Time to insulin in the Trial Evaluating Cardiovascular Outomes with Sitagliptin (TECOS) 2017
- Sex differences in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) 2016
- Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial 2016
- Greater dissociation of apolipoprotein B and LDL cholesterol targets in diabetes versus non-diabetes patients receiving lipid-lowering therapy 2011
- Successful transitions from MDI therapy to sensor-augmented pump therapy in the STAR 3 study: system settings and behaviours 2011
- Distinctive metabolic signature in subjects with early onset type 2 diabetes 2010
- Glucose control in adults during a 1-year randomised controlled trial comparing sensor-augmented pump therapy and multiple daily injection therapy: STAR 3 study 2010
- Glycaemia management of minority participants in ACCORD 2010
- Effect of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in type IIa and IIb hyperlipidaemia (HL) patients with diabetes (DM) or metabolic syndrome (MS) 2008
- The safety and efficacy of ezetimibe/simvastatin (E/S) versus atorvastatin (A) in hypercholesterolaemic (HC) patients with type 2 diabetes (T2DM) 2006
- Diabetes patients' stated preference for insulin therapies: trading health for convenience 2004
- Risking health to avoid injections: stated preferences of Canadians with diabetes 2004